Support in USA : 1-978- 707-9553 / Support in India : +91- 9987711567

  • Apple Pharmaceuticals

Imatib 400 mg

Anticancer-Cancer-Treatment-Cipla-Imatinib-Mesylate-400mg-Imatib

Availability: In stock

Special Price $ 225

BRAND : Imatib 400 mg
STRENGTH : 400mg
INGREDIENT : Anticancer-Cancer-Treatment-Cipla-Imatinib-Mesylate-400mg-Imatib
COMPANY NAME : Cipla
COUNT : 3x10TABS Tablets



Description of Imatib 400 mg

Brand name: Imatib
Generic name: Imatinib mesylate
Manufacturer: cipla
Strength: 400mg
Category: Anti-neoplastic agent
Container: 30 tablets in a bottle
Product Description:
Imatib tablet is an anti cancer medicine which is useful for treating;
• Advanced myelogenous leukemia (CML),
• Gastrointestinal stromal tumors (GISTs) and a number of malignancies
Imatib is a tyrosine kinase inhibitor that prohibits BCR-ABL kinase produced by chromosomal rearrangement in chronic myeloid leukemia and acute lymphoblastic leukemia
PDG-derived tyrosine kinase that are expressed in gastrointestinal stromal tumor
Imatib is used as monotherapy, or it may combine with some other medicine in the conditions of certain types of cancer or bone marrow disorders.

Pharmacology of Imatib 400 mg

Mechanism of action:
Imatib contains an active chemical substance known as Imatinib mesylate; it is an inhibitor of certain tyrosine kinase enzymes.
Imatib prohibits BCR-ABL tyrosine kinase (atypical enzyme produced by Philadelphia chromosome abnormality in CML)
Imatib obstruct the multiplication and promote the apoptosis in BCR-ABL positive cells in addition to fresh leukemia cells from Philadelphia chromosome positive CML
Imatib also prohibits tumor growth of BCR-ABL transacted murine myeloid cells along other BCR-ABL positive leukemia CML in blast crisis
Pharmacokinetic:
Absorption:
After an oral administration of Imatib tablets, it is largely absorbed within 2-4 hours. The bioavailability of Imatib tablets is about 98%.
Distribution:
Imatinib is highly bound to the human plasma protein almost range of 95%. It is mostly bound to albumin and α1-acid glycoprotein.
Metabolism:
The major enzyme which is essential for metabolism of Imatib tablet is CYP3A4.
Active metabolite of Imatinib is N-demethylated piperizine derivative
Excretion:
The elimination of Imatinib is predominantly occurred in feces.
Nearly 81% of the drug excreted within 7 days through feces and 13% of drug through urine.
The half life time of Imatinib and active metabolite N-demethyl derivative (CGP74588) are around 18 and 40 hours respectively

Indication of Imatib 400 mg

Imatib tablets are primarily indicated for the treatment of;
Aggressive systemic mastocytosis
Chronic esinophillic leukemia
Dermatofibrosarcoma protuberans
Gastrointestinal stromal tumors
Hyperesinophillic syndrome
Myelodysplastic syndrome
Myeloproliferative disease
Philadelphia chromosome positive acute lymphoblastic leukemia
Philadelphia chromosome positive chronic myeloid leukemia

Dose & Dosage's of Imatib 400 mg

The prescribed dose of tablet Imatib is 400mg or 600mg as a single dose. Whereas 800mg which is administered as 400mg twice daily.
Imatib tablets should be taken with food
The recommended dose for following conditions;
Acute lymphoblastic leukemia:
In adults, the recommended dose is 600mg should be taken orally as a single dose.
Myelodysplastic/Myeloproliferative diseases:
The prescribed dose is 400mg PO qDay
Hyperesinophillic syndrome:
In this condition, prescribed dose is 400mg PO qDay
Chronic myeloid leukemia:
Chronic phase: In newly diagnosed patients, the dose of Imatib tablet is 400mg should be orally taken as a single dose.
If chronic phase is failed with the treatment of interferon alpha therapy; dose is increased to 600mg per day.
Accelerated phase: 600mg PO qDay; dose should be vary to 400mg PO as twice daily if there is no severe adverse drug reaction or non leukemia associated neutropenia or thrombocytopenia.
Dermatofibrosarcoma protuberans:
Recommended dose is 400mg PO q12hr
Mastocytosis:
Without D816V c-kit mutation: 100mg per oral for qDay
c-kit mutational status unknown: 400mg per oral qDay
ASM related with esinophillic: 100mg PO qDay initially increased to 400mg/day.
Gastrointestinal stromal tumors
The prescribed dose of the tablet Imatib is 400mg should be taken orally as a twice daily
In pediatric:
Chronic myeloid leukemia:
<1 year: the safety and efficacy of the drug has not been established
≥1 year: 340mg/m2/day PO; should not be exceed 600mg/day
Acute lymphoblastic leukemia:
<1 year: the safety and efficacy of the drug has not been established
≥1 year: 340mg/m2/day PO; should not be exceed 600mg/day

Side Effects of Imatib 400 mg

Pericardial effusion
Tachycardia
Pulmonary edema
Atrial fibrillation
Cardiac arrest, myocardial infraction
Angina
Reynaud’s syndrome
Dry skin, Stevens Johnson syndrome, acute febrile neutrophillic dermatosis
Ulcer, dysphasia, esophagitis, dry mouth
Gastro esophageal reflux
Weakness, anasarca, chills, malaise
Pancytopenia
Febrile neutropenia
Lymphopenia, esinophillia
Thrombocythemia
Bone marrow depression
Lymphadenopathy, hemolytic anemia, Aplastic anemia
Hepatitis, jaundice, hepatic failure, hepatic necrosis
Angioedema
Hyperuricemia
Hypocalcaemia
Hyperglycemia
Hyponatremia
Hyperkelamia, hypomagnesemia
Joint swelling, muscle stiffness, muscular weakness, arthritis
Paresthesia, hypesthesia, syncope, peripheral neuropathy, somnolence, tremor
Hematuria, renal pain
Gynecomastia, erectile dysfunction
Menstruation irregular, nipple pain, scrotal edema
Glaucoma

Contraindication of Imatib 400 mg

Hypersensitive reaction to Imatinib mesylate and other excipients present in Veenat tablets

Drug Interaction of Imatib 400 mg

Imatib tablets are primarily indicated for the treatment of; Aggressive systemic mastocytosis Chronic esinophillic leukemia Dermatofibrosarcoma protuberans Gastrointestinal stromal tumors Hyperesinophillic syndrome Myelodysplastic syndrome Myeloproliferative disease Philadelphia chromosome positive acute lymphoblastic leukemia Philadelphia chromosome positive chronic myeloid leukemia

Precaution of Imatib 400 mg

Caution with use in hepatic impairment patients
Avoid combination with strong CYP3A4 inducers
Risk of severe CHF or ventricular dysfunction
Hemorrhage occurs
Growth retardation occurs in children

Usage & Safety profile of Imatib 400 mg Pregnancy & Lactation

Pregnancy category: D Imatib should not recommended to pregnant and breast feeding mothers, it can able to cause fetal malformations and cause fetal harm The metabolites excreted in human milk

Storage of Imatib 400 mg

Imatib tablet container should be stored in cool and dry place
It should be keep away from moisture, heat and light